- Home
- SYRE vs IMTX Comparison
SYRE vs IMTX Comparison
Compare SYRE & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- IMTX
- Stock Information
- Founded
- SYRE 2013
- IMTX N/A
- Country
- SYRE United States
- IMTX Germany
- Employees
- SYRE N/A
- IMTX N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYRE Health Care
- IMTX Health Care
- Exchange
- SYRE Nasdaq
- IMTX Nasdaq
- Market Cap
- SYRE 1.1B
- IMTX 865.5M
- IPO Year
- SYRE 2016
- IMTX N/A
- Fundamental
- Price
- SYRE $16.23
- IMTX $9.39
- Analyst Decision
- SYRE Strong Buy
- IMTX Strong Buy
- Analyst Count
- SYRE 6
- IMTX 5
- Target Price
- SYRE $57.60
- IMTX $15.00
- AVG Volume (30 Days)
- SYRE 681.2K
- IMTX 815.8K
- Earning Date
- SYRE 11-06-2025
- IMTX 11-17-2025
- Dividend Yield
- SYRE N/A
- IMTX N/A
- EPS Growth
- SYRE N/A
- IMTX N/A
- EPS
- SYRE N/A
- IMTX N/A
- Revenue
- SYRE N/A
- IMTX $152,823,253.00
- Revenue This Year
- SYRE N/A
- IMTX N/A
- Revenue Next Year
- SYRE N/A
- IMTX N/A
- P/E Ratio
- SYRE N/A
- IMTX N/A
- Revenue Growth
- SYRE N/A
- IMTX 83.61
- 52 Week Low
- SYRE $10.91
- IMTX $3.30
- 52 Week High
- SYRE $40.26
- IMTX $11.40
- Technical
- Relative Strength Index (RSI)
- SYRE 52.04
- IMTX 78.64
- Support Level
- SYRE $15.87
- IMTX $6.90
- Resistance Level
- SYRE $17.18
- IMTX $9.54
- Average True Range (ATR)
- SYRE 0.88
- IMTX 0.47
- MACD
- SYRE 0.08
- IMTX 0.25
- Stochastic Oscillator
- SYRE 70.65
- IMTX 95.21
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.